Results 261 to 270 of about 54,248 (321)

The effect of trimetazidine on cardiac haemodynamics and mitochondrial function in wild‐type transthyretin amyloidosis

ESC Heart Failure, EarlyView.
Abstract Aims Wild‐type transthyretin cardiac amyloidosis (ATTRwt) is a cardiomyopathy causing myocardial hypoperfusion and impaired cardiac mitochondrial function. Trimetazidine is an antianginal agent used in patients with stable angina pectoris, which improves cardiac contractility and mitochondrial function.
Bertil Thyrsted Ladefoged, Anders Lehmann Dahl Pedersen, Anne Mette Dybro, Tor Skibsted Clemmensen, Julian Gillmore, Steen Hvitfeldt Poulsen   +5 more
wiley   +1 more source

Transthoracic echocardiographic reference intervals in 214 adult Golden retrievers. [PDF]

J Vet Med Sci
Bagardi M, Ferrari P, Locatelli C, Ghilardi S, Zanchi F, Vezzosi T, Porciello F, Rishniw M, Brambilla PG.   +8 more
europepmc   +1 more source

Diastole matafaoi: Mollusc Specialist Group

, 1996

openalex   +1 more source

ATF6β is not essential for the development of physiological cardiac hypertrophy. [PDF]

PLoS One
Davis E, Shokri MR, Rowland MB, York T, Cohen CT, Johnson AG, Moore PE, Schweitzer S, Sin J, Bui C, Correll RN.   +10 more
europepmc   +1 more source

Vericiguat improves cardiac remodelling and function in rats with doxorubicin‐induced cardiomyopathy

ESC Heart Failure, EarlyView.
Abstract Purpose Vericiguat, a soluble guanylate cyclase (sGC) stimulator, has been demonstrated effective in improving prognosis of patients with heart failure with reduced ejection fraction. However, there are limited data concerning the effect of vericiguat in patients with doxorubicin (DOX)‐induced cardiomyopathy (DIC).
Wen Chen, Ying Wu, Wei Li, Meiyan Song, Kaizu Xu, Meifang Wu, Liming Lin   +6 more
wiley   +1 more source

Advancing diagnostics and therapy in transthyretin amyloid cardiomyopathy

ESC Heart Failure, EarlyView.
Katarzyna Holcman, Michał Tkaczyszyn
wiley   +1 more source

Up‐titration of medication in patients with new‐onset heart failure with and without atrial fibrillation

ESC Heart Failure, EarlyView.
Abstract Aims Differences in guideline‐directed medical therapy (GDMT) and clinical outcomes have been observed between heart failure (HF) patients with atrial fibrillation (AF) versus those in sinus rhythm. This study evaluated the effects of up‐titration of HF therapies, consisting of beta‐blockers, angiotensin‐converting‐enzyme inhibitors (ACEis ...
Arietje J.L. Zandijk, Bernadet T. Santema, Friso D.J. Inkelaar, Martje H.L. van der Wal, Janke Warink‐Riemersma, Michiel Rienstra, Adriaan A. Voors   +6 more
wiley   +1 more source

The Critical Role of Comorbidities in Managing Heart Failure with Preserved Ejection Fraction (HFpEF)

ESC Heart Failure, EarlyView.
Piotr Gajewski, Robert Zymlinski, Jan Biegus   +2 more
wiley   +1 more source

The ADESTE trial: A phase 2 study of enibarcimab, a monoclonal antibody targeting adrenomedullin, in acute heart failure

ESC Heart Failure, EarlyView.
Abstract Aims This study aimed to conduct a phase 2 proof‐of‐concept and safety study to evaluate the effect of ENIBARCIMAB (EN), a non‐neutralizing humanized monoclonal antibody targeting the N‐terminus of adrenomedullin (ADM), administered immediately after stabilization with standard of care (SoC) treatment, in patients hospitalized for acute heart ...
Anggoro Budi Hartopo, Arinal Chairul Achyar, Hendry Purnasidha Bagaswoto, Firandi Saputra, Hasanah Mumpuni, Dyah Adhi Kusumastuti, Teguh Triyono, Usi Sukorini, Metalia Puspitasari, Budi Yuli Setianto, Mohammad Saifur Rohman, Muhammad Anshory, Yoga Waranugraha, Putri Annisa Kamila, Agustin Iskandar, Hani Susianti, Andreas Bergman, Claudia Knothe, Paola Antonini, Salvatore Di Somma   +19 more
wiley   +1 more source

Discovery of miRNAs unique to actively transcribed erythroparvovirus infection in heart failure patients

ESC Heart Failure, EarlyView.
Abstract Aims miRNAs, small non‐coding RNAs, play key roles in gene regulation, cell differentiation and tissue development. They influence viral infection outcomes by directly interacting with viral genomes or modifying the host microenvironment. This study demonstrates miRNAs' ability to selectively suppress transcriptionally active erythroparvovirus,
Ganna Aleshcheva, Sara Salih, Christian Baumeier, Felicitas Escher, C. Thomas Bock, Heinz‐Peter Schultheiss   +5 more
wiley   +1 more source